TLSI

TriSalus Life Sciences (TLSI)

TriSalus Life Sciences Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:TLSI

1 2 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/15	21:00	Business Wire	TriSalus Reports Q1 2024 Financial Results and Business Update	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/05/07	20:00	Business Wire	TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/05/07	05:58	Business Wire	TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/05/01	05:35	Business Wire	TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/04/01	21:00	Business Wire	TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/03/26	21:00	Business Wire	TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/03/21	21:00	Business Wire	TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/03/12	06:15	Business Wire	TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/03/07	21:00	Business Wire	TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/02/29	21:00	Business Wire	TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/02/15	08:42	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/02/15	08:39	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/02/15	08:36	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/02/15	08:19	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/02/15	08:13	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/01/26	07:43	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/01/26	07:23	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/01/26	07:21	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/01/26	07:19	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TLSI	TriSalus Life Sciences Inc
2024/01/06	06:28	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TLSI	TriSalus Life Sciences Inc
2023/12/27	14:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:TLSI	TriSalus Life Sciences Inc
2023/12/27	14:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:TLSI	TriSalus Life Sciences Inc
2023/12/27	07:28	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:TLSI	TriSalus Life Sciences Inc
2023/12/27	07:27	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:TLSI	TriSalus Life Sciences Inc
2023/11/14	22:00	Business Wire	TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update	NASDAQ:TLSI	TriSalus Life Sciences Inc
2023/11/08	06:05	Business Wire	TriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference Call	NASDAQ:TLSI	TriSalus Life Sciences Inc
2023/11/05	03:25	Business Wire	Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications	NASDAQ:TLSI	TriSalus Life Sciences Inc
2023/11/04	01:00	Business Wire	TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting	NASDAQ:TLSI	TriSalus Life Sciences Inc
2023/10/25	22:05	Business Wire	TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting	NASDAQ:TLSI	TriSalus Life Sciences Inc
2023/10/19	10:58	Edgar (US Regulatory)	Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]	NASDAQ:TLSI	TriSalus Life Sciences Inc